Prurigo Nodularis Market Insights, Epidemiology and Market Forecast-2030

Albany, NY -- (SBWire) -- 05/26/2020 --Prurigo Nodularis Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Prurigo Nodularis Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. The total diagnosed Prurigo Nodularis prevalent population in the 7MM was found to be 539,893 in 2017.
2. The total diagnosed prevalent patient population of Prurigo Nodularis in the 7MM was around 46.30% of the total cases in the United States in 2017.
3. Females are affected more by Prurigo Nodularis as compared to males.

Key benefits of the report
1. Prurigo Nodularis market report covers a descriptive overview and comprehensive insight of the Prurigo Nodularis epidemiology and Prurigo Nodularis market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Prurigo Nodularis market report provides insights into the current and emerging therapies.
3. Prurigo Nodularis market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Prurigo Nodularis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Prurigo Nodularis market.

Request for sample pages

"Prurigo Nodularis market was USD 344.89 Million in the United States in 2017."

Prurigo Nodularis treatment is challenging. The current Prurigo Nodularis market can be classified based on the severity of the disease as mild, moderate, and severe. There is a multimodal treatment algorithm consisting of topical and systemic therapies, where topical therapies are used for treating the visible form of the disease. In contrast, systemic therapies are used for symptomatic treatment. The symptomatic therapy aims to reduce itching and complete healing of lesions. A mild form of the disease includes several topical therapies, such as antihistamines, topical corticosteroids, topical immunosuppressants, topical calcineurin inhibitors, emollients, which are recommended as both an essential therapy and general therapeutic measure.

Topical corticosteroid includes Betamethasone 0.1% cream, which reduces itch significantly, in comparison with an antipruritic moisturizing cream, and also results in nodule flattening. Topical calcineurin inhibitors or immunosuppressants represent a relatively long-term treatment option.

On the other hand, for moderate-to-severe forms of the disease, topical corticosteroids (Betamethasone 0.1%), topical Immunosuppressants/Topical calcineurin inhibitors (pimecrolimus and Tacrolimus), systemic immunosuppressants (for moderate-to-severe cases), systemic corticosteroid (triamcinolone acetonide) along with other relevant therapies such as antidepressants (paroxetine, amitriptyline or mirtazapine), gabapentinoids and opioid receptor antagonists are suggested usually.

Immunosuppressants are considered as a therapeutic option for patients with moderate-to-severe Prurigo Nodularis mainly. Several studies have described the application of immunosuppressive agents, such as cyclosporine in the disease, showing remarkable symptom improvement. During immunosuppressant therapy, it is essential to monitor blood pressure and laboratory values, especially those of the kidneys. Thalidomide and its analogue Lenalidomide are other immunomodulatory drugs that have successfully been used to treat refractory cases of Prurigo Nodularis.

The launch of the emerging therapies is expected to significantly impact Prurigo Nodularis treatment scenario in the upcoming years:-

Drugs covered
1. Serlopitant
2. Nalbuphine ER
3. Nemolizumab (CD14152)
4. Apremilast (CC-10004)
5. M 118103
6. KPL-716
7. Dupixent (Dupilumab/SAR231893)
And many others

The key players in Prurigo Nodularis market are:
1. Menlo Therapeutics
2. Trevi Therapeutics
3. Galderma
4. Amgen
5. Maruho
6. Kiniksa Pharmaceuticals
7. Sanofi
8. Regeneron Pharmaceuticals
And many others

Table of contents
1 Key Insights
2 Prurigo Nodularis Patient Overview at a Glance
3 Executive Summary
4 SWOT Analysis
5 Disease Background and Overview of Prurigo Nodularis
6 Recognized Establishments
7 Prurigo Nodularis Epidemiology and Patient Population
8 Country-wise Epidemiology of Prurigo nodularis
8.1 United States
8.2 EU5 Countries
8.3 Germany
8.4 France
8.5 Italy
8.6 Spain
8.7 United Kingdom
8.8 Japan
9 Prurigo Nodularis Treatment
10 European Guidelines on Prurigo Nodularis
11 FDA Recommendations for Prurigo Nodularis Treatment
12 Unmet Need
13 Prurigo Nodularis Emerging Drugs
13.1 Key Competitors
13.2 Serlopitant: Menlo Therapeutics
13.3 Nalbuphine ER: Trevi Therapeutics
13.4 Nemolizumab (CD14152): Galderma
13.5 Apremilast (CC-10004): Amgen
13.6 M 118103: Maruho
13.7 KPL-716: Kiniksa Pharmaceuticals
13.8 Dupixent (Dupilumab/SAR231893): Sanofi/Regeneron Pharmaceuticals
14 Prurigo Nodularis Market Size
15 Attribute Analysis
16 Conjoint Analysis
17 7MM Prurigo Nodularis Market Outlook
17.1 United States
18 EU5 Countries
18.1 Germany
18.2 France
18.3 Italy
18.4 Spain
18.5 United Kingdom
19 Japan
20 Case Reports
21 Market Drivers
22 Market Barriers
23 Appendix
24 Prurigo Nodularis Report Methodology
25 DelveInsight Capabilities
26 Disclaimer
27 About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight